Kestra Advisory Services’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Kestra Advisory Services’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,532	Closed	-$2.19K	–	2261
2023 Q2	$2.19K	Hold	11,532	–	–	﹤0.01%	2100
2023 Q1	$3.92K	Hold	11,532	–	–	﹤0.01%	2043
2022 Q4	$3.73K	Hold	11,532	–	–	﹤0.01%	2244
2022 Q3	$5K	Hold	11,532	–	–	﹤0.01%	2096
2022 Q2	$5K	Hold	11,532	–	–	﹤0.01%	2122
2022 Q1	$15K	Hold	11,532	–	–	﹤0.01%	1986
2021 Q4	$15K	Hold	11,532	–	–	﹤0.01%	1997
2021 Q3	$24K	Hold	11,532	–	–	﹤0.01%	2101
2021 Q2	$18K	Hold	11,532	–	–	﹤0.01%	1991
2021 Q1	$26K	Hold	11,532	–	–	﹤0.01%	1843
2020 Q4	$29K	Hold	11,532	–	–	﹤0.01%	1835
2020 Q3	$28K	Buy	+11,532	New	+$33.6K	﹤0.01%	1396

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Kestra Advisory Services's NYMX Position: Q3 2023 in Review

Kestra Advisory Services sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 11,532 shares — an estimated $2.19K sold.

Kestra Advisory Services first reported a position in NYMX in Q3 2020 and held it in 12 quarters. The position peaked at $29K in Q4 2020. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Kestra Advisory Services reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Kestra Advisory Services sold 11,532 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $2.19K.
Kestra Advisory Services first reported a position in Nymox Pharmaceutical Corp in Q3 2020 and held it in 12 quarters.
Kestra Advisory Services's Nymox Pharmaceutical Corp position peaked at $29K in Q4 2020.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Kestra Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.